- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00607711
Study of Oral Palifosfamide Tris in Solid Tumors
April 30, 2008 updated by: Alaunos Therapeutics
A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors
The study of maximum tolerated dose and safety of oral palifosfamide tris capsules in advanced, refractory, solid tumors
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with histological or cytological confirmation of advanced cancer that is refractory to standard therapies for their condition.
- Men and women of ≥18 years of age.
- Life expectancy of at least 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance score ≤2 (see Appendix 4).
- Eligible subjects MUST have at least one measurable lesion as defined by RECIST guidelines. If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology. Measurable lesions must NOT have been in a previously irradiated field or injected with biological agents.
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements, to be conducted ≤2 weeks prior to Baseline:
- Creatinine < 1.5× upper limit of normal (ULN) OR a calculated creatinine clearance ≥70 cc/min
- Total bilirubin ≤2×ULN
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN
- Granulocytes in peripheral blood ≥2.0×109/L, hemoglobin ≥8.5 g/dL, and platelets ≥50,000/µL
- Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee (IEC/IRB) having jurisdiction over the site.
- Men and women of childbearing potential must use effective contraception from Screening through his/her duration of study participation.
- Women of childbearing potential must have a negative serum pregnancy test prior to entering the study.
Exclusion Criteria:
- New York Heart Association (NYHA) functional Class ≥III myocardial infarction (see Appendix 5) within 6 months.
- Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc ≥450 msec; or a ≥Grade 2 atrioventricular (AV) block or left bundle branch block (LBBB); or documented history of prolonged QTc.
- Pregnancy and/or lactation.
- Uncontrolled systemic infection (documented with microbiological studies).
Inadequate renal function as defined by the presence of one or more of the following:
- Creatinine clearance (CrCl) <70 cc/min
- Serum creatinine >1.5×ULN
- Prior nephrectomy
- Urinary tract obstruction
- Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry (mitomycin C or nitrosureas should not be given within 6 weeks of study entry).
- Radiotherapy during study or within 3 weeks of study entry.
- Surgery within 4 weeks of start of study drug.
- Other investigational drug therapy outside of this trial during or within 4 weeks of study entry.
- History of invasive second primary malignancy diagnosed within the previous 3 years except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer.
- Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study or evaluation of study results.
- Any condition that is unstable or could jeopardize the safety of the subject and his/her compliance in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
|
Capsule(s) given daily for 15 days followed by a 6 day rest.
This is a dose escalation arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicities
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sachin Shah, MD, ZIOPHARM Oncology, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Anticipated)
November 1, 2009
Study Completion (Anticipated)
November 1, 2009
Study Registration Dates
First Submitted
January 24, 2008
First Submitted That Met QC Criteria
January 24, 2008
First Posted (Estimate)
February 6, 2008
Study Record Updates
Last Update Posted (Estimate)
May 5, 2008
Last Update Submitted That Met QC Criteria
April 30, 2008
Last Verified
January 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IPC1001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
Clinical Trials on oral palifosfamide tris
-
Alaunos TherapeuticsUnknownAdvanced Solid TumorsUnited States
-
Alaunos TherapeuticsUnknownCancer | Small Cell Lung Cancer | Ovarian Cancer | Thymoma | Osteosarcoma | Non Small Cell Lung Cancer | Malignancy | Testicular CancerUnited States
-
Alaunos TherapeuticsUnknownExtensive-Stage Small Cell Lung CancerUnited States, Canada, Taiwan, Israel, Italy, Australia, France, Hungary, Poland, Russian Federation, United Kingdom
-
Alaunos TherapeuticsUnknownSoft Tissue SarcomaUnited States, Italy, Romania
-
Alaunos TherapeuticsCompletedSoft Tissue SarcomaUnited States, France, Spain, Belgium, Argentina, Colombia, Israel, India, Romania, Australia, Canada, Singapore, Russian Federation, Brazil, Chile, Germany, Guatemala, Italy, Panama, Poland, United Kingdom
-
AerasNational Institute of Allergy and Infectious Diseases (NIAID); Sanofi Pasteur... and other collaboratorsCompletedTuberculosisSouth Africa
-
Alaunos TherapeuticsCompletedBreast Cancer Nos Metastatic RecurrentUnited States
-
AerasStatens Serum InstitutCompleted
-
Bavarian NordicCompleted
-
NeuroTrauma Sciences, LLCParexelRecruitingAcute Ischemic StrokeUnited States